Skip To Main Content
Campus
  • Terapiområder
  • Artikler
  • Materiell
Campus
  • Terapiområder
  • Artikler
  • Materiell
View Full Results

Uncovering the Hidden Burden: Understanding Loss of Smell in CRSwNP

Author : This document has been created by Sanofi and reviewed by Professor Peter Hellings, University of Leuven, Belgium
Editorial Team

Navigating the Complexities of Smell Loss in Patients with CRSwNP.

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a prevalent condition that significantly impacts the quality of life for many individuals, particularly through the loss of smell. This booklet delves into the complexities of olfactory dysfunction associated with CRSwNP, exploring its causes, symptoms, and the profound effects it has on daily living. With insights from recent research, we aim to shed light on the often-overlooked burden of losing one's sense of smell.

How does the loss of smell affect CRSwNP patients? Read this booklet to discover more about the hidden challenges faced by patients with CRSwNP.

DOWNLOAD

Referanser

  1. Bachert C, et al. J Asthma Allergy. 2021;14:127–134.

  2. Chen S, et al. Curr Med Res Opin. 2020;36(11):1897–1911.

  3. Fokkens WJ, et al. Rhinology. 2024;62(3):287–298.

  4. Passali GC, et al. Eur Arch Otorhinolaryngol. 2022;279(2):773–777.

  5. Chaaban MR, et al. Am J Rhinol Allergy. 2013;27(6):473–478.

  6. Claeys N, et al. Front Allergy. 2021;2:761388.

  7. Luke L, et al. J Clin Med. 2023;12(16)5367.

  8. Schlosser RJ, et al. Int Forum Allergy Rhinol. 2020;10(1):7–14.

  9. Benson VS, et al. OTO Open. 2022;6(4):2473974X221128930.

  10. De Corso E, et al. J Pers Med. 2022;12(6)846.

  11. Peters AT, et al. Clin Exp Allergy. 2022;52(9):1105–1109.

  12. Desai M and Oppenheimer J. J Allergy Clin Immunol Pract. 2021;9(1):7–12.

  13. Ahmed OG and Rowan NR. Immunol Allergy Clin North Am. 2020;40(2):223–232.

  14. Qureshi HA and Lane AP. Am J Rhinol Allergy. 2023;37(2):168–174.

  15. Song J, et al. Expert Rev Clin Immunol. 2023;19(8):993–1004.

  16. Dekeyser A, et al. Int J Mol Sci. 2024;25(8):4460.

  17. Czerwaty K, et al. Diagnostics (Basel). 2022;12(10)2361.

  18. Rodenkirch C, et al. Front Neurosci. 2022;16:922424.

  19. Shah SA and Kobayashi M. Heliyon. 2023;9(9):e19249.

  20. Stevens WW, et al. J Allergy Clin Immunol Pract. 2019;7(8):2812–2820.

  21. Zhang Z, et al. Am J Otolaryngol. 2022;43(5):103561.

  22. Fokkens WJ, et al. Allergy. 2019;74(12):2312–2319.

  23. Kohli P, et al. Laryngoscope. 2017;127(2):309–320.

  24. Rouyar A, et al. Allergy. 2019;74(3):549–559.

  25. Chaker A, et al. Laryngorhinootologie. 2023;102(S 02).

  26. Hara Y, et al. Journal of Allergy and Clinical Immunology. 2023;151(2):AB128.

  27. Soler ZM, et al. Int Forum Allergy Rhinol. 2020;10(3):343–355.

  28. Laidlaw TM and Buchheit KM. Ann Allergy Asthma Immunol. 2020;124(4):326–332.

  29. Bao K and Reinhardt RL. Cytokine. 2015;75(1):25–37.

  30. Chiang S and Lee SE. Am J Rhinol Allergy. 2023;37(2):193–197.

  31. Takabayashi T, et al. Am J Respir Crit Care Med. 2013;187(1):49–57.

  32. Takabayashi T, et al. J Allergy Clin Immunol. 2013;132(3):584–592.

  33. Kariyawasam HH, et al. Drug Des Devel Ther. 2020;14:1757–1769.

  34. Zhu Z, et al. J Clin Invest. 1999;103(6):779–788.

  35. Yu L, et al. J Inflamm Res. 2017;10:181–188.

  36. Saraswathula A, et al. Int Forum Allergy Rhinol. 2023;13(3):230–241.

  37. Rael EL and Lockey RF. World Allergy Organ J. 2011;4(3):54–64.

  38. Bullens DM, et al. Clin Exp Immunol. 1999;118(3):384–91.

  39. Gevaert P, et al. Int Forum Allergy Rhinol. 2022;12(11):1413–1423.

  40. Shen S, et al. Asia Pac Allergy. 2024;14(1):26–31.

  41. Li J, et al. Allergy Asthma Clin Immunol. 2019;15:71.

  42. Kimura S, et al. Allergy Asthma Immunol Res. 2011;3(3):186–193.

  43. GlaxoSmithKline. Nucala® Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/nucalaepar-product-information_en.pdf. Last updated 16/07/2024. Last accessed Oct 2024

  44. Sanofi and Regeneron. Dupixent® Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/dupixentepar-product-information_en.pdf. Last updated 15/07/2024. Last accessed Oct 2024.

  45. Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (WAYPOINT). NCT04851964. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04851964?cond=Chronic%20Rhinosinusitis&intr=Tezepelumab&rank=1 [Last accessed October 2024].

  46. Rumeau C, et al. Eur Ann Otorhinolaryngol Head Neck Dis. 2016;133(3):203–206.

  47. Oleszkiewicz A, et al. Eur Arch Otorhinolaryngol. 2019;276(3):719–728.

  48. Brumm MC, et al. Neurology. 2023;100(16):e1691–e1701.

  49. Muirhead N, et al. Otorhinolaryngologist. 2013;6:99–103.

  50. Mullol J, et al. J Allergy Clin Immunol. 2020;145(3):773–776.

  51. Luke L, et al. Curr Otorhinolaryngol Rep. 2022;10(4):377–384.

  52. Types of Tests Used to Evaluate Hearing in Children and Adults. American Speech-Language-Hearing Association. https://www.asha.org/public/hearing/types-of-tests-used-to-evaluate-hearing/ [Last accessed August 2024].

  53. Macchi A, et al. Front Allergy. 2023;4:1083964.

  54. Bakhshaee M, et al. Iran J Otorhinolaryngol. 2016;28(85):125–134.

  55. Bachert C, et al. J Allergy Clin Immunol. 2021;147(1):29–36.

  56. Fokkens WJ, et al. Rhinology. 2020;(Suppl.29):1–464.

Dette kan også være av interesse
MAT-BE-2400974-v1.0-10/2024